Autoimmune Encephalitis Clinical Trial
Official title:
A Phase 2a, Prospective, Open-label, Single-arm, Single Center, Proof of Concept Study to Evaluate the Safety and Efficacy of IGIV 10% in Patients With Autoimmune Encephalitis
Verified date | June 2020 |
Source | Green Cross Corporation |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to evaluate the safety and efficacy of IGIV 10% in patients with autoimmune encephalitis
Status | Completed |
Enrollment | 23 |
Est. completion date | June 11, 2020 |
Est. primary completion date | June 11, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 12 Years and older |
Eligibility |
Inclusion Criteria: 1. Male or female, aged more than 12 years.(adolescent or adult) 2. Subject who all three of the following diagnosis criteria for possible autoimmune encephalitis have been met. - Subacute onset (rapid progression of less than 3 months) of working memory deficits(short-term memory loss), altered mental status, or psychiatric symptoms. - At least one of the following: - New focal CNS findings - Seizure not explained by a previously known seizure disorder - CSF pleocytosis (WBC count = 5/mm2) - MRI features suggestive of encephalitis - Reasonable exclusion of alternative causes 3. Subjects or parent/legal representative willing to provide written informed consent Exclusion Criteria: 1. Subject who has received Immunoglobulin therapy within 10 weeks prior to screening 2. Subject who has a history of hypersensitivity or shock to ingredient of immunoglobulin 3. Subject who has been diagnosed with IgA deficiency 4. Subject who has renal disorder (creatinine clearance < 10 ml/min) or requires dialysis 5. Subject who has been diagnosed with hemolytic anemia or anemia from blood loss 6. Subject who has been diagnosed with immuonological competence or immunodeficiency 7. Subject who has high risk of thrombus or embolism (History of thrombus/embolism or cerebro/cardiovascular disorder within 3 months prior to screening) 8. Subject who has low heart condition (Congestive heart failure >NYHA functional class ?: unstable coronary artery disease or myocardiac infarction within 3 months prior to screening) 9. Subject who cannot prohibit the previously administrated steroids by investigator's discretion (ex. Suspicion of steroid dependence, hypoadrenocorticism, when treatment effects are expected, etc.) 10. Females who are pregnant or breast feeding 11. Subject who is considered by investigator to ineligible for the study. |
Country | Name | City | State |
---|---|---|---|
Korea, Republic of | Seoul National University Hospital | Seoul |
Lead Sponsor | Collaborator |
---|---|
Green Cross Corporation |
Korea, Republic of,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Chage of mRS(The Modified Rankin Scale) score; 0(better) to 6(worse) | Change of mRS score 7 days and 28 days after IP administration compared with baseline(before IP administration) | 28 days | |
Secondary | Chage and improvement of mRS(The Modified Rankin Scale) score; 0(better) to 6(worse) | Change and improvment of mRS score 14 days and 28 days after IP administration compared with baseline(before IP administration) | 28 days | |
Secondary | Chage and improvement of Glasgow coma scale(GCS); 3(worse) to 15(better) | Change and improvment of Glasgow coma scale(GCS) 7 days, 14 days and 28 days after IP administration compared with baseline(before IP administration) | 28 days | |
Secondary | Chage and improvement of Clinical Global Impression Scale-Severity; 1(better) to 7(worse) | Change and improvment of Clinical Global Impression Scale-Severity 7 days, 14 days and 28 days after IP administration compared with baseline(before IP administration) | 28 days | |
Secondary | Chage and improvement of Clinical Global Impression Scale-Impovement; 1(better) to 7(worse) | Change and improvment of Clinical Global Impression Scale-Improvement 7 days, 14 days and 28 days after IP administration compared with baseline(before IP administration) | 28 days | |
Secondary | Chage and improvement of CASE(Clinical Assessment scale of Encephalitis) score; 0(better) to 27(worse) | Change and improvment of CASE score 7 days, 14 days and 28 days after IP administration compared with baseline(before IP administration) | 28 days | |
Secondary | The relationship | The relationship between neurological scale | 28 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04561557 -
Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System
|
Early Phase 1 | |
Completed |
NCT05645185 -
Characterisation of Clinical Phenotypes and Outcomes of Ma2 Patient
|
||
Not yet recruiting |
NCT04106596 -
HLA Analysis in Autoimmune Encephalitis and Related Disorders
|
||
Completed |
NCT04708626 -
Epidemiology of Autoimmune Encephalitides and Paraneoplastic Neurological Syndromes in Sweden
|
||
Not yet recruiting |
NCT05711563 -
Predicting and Monitoring Outcomes in Autoimmune Encephalitis
|
||
Recruiting |
NCT03194815 -
IVIG and Rituximab in Antibody-associated Psychosis - SINAPPS2
|
Phase 2 | |
Recruiting |
NCT06079294 -
Impact of Confirmed Autoimmune Encephalitis on Brain Glucose Metabolism
|
N/A | |
Not yet recruiting |
NCT03957616 -
Incidence of Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis
|
||
Completed |
NCT02905136 -
Mechanisms of Auto-immune Encephalitis
|
||
Recruiting |
NCT05280600 -
Developing Advanced Neuroimaging for Clinical Evaluation of Autoimmune Encephalitis
|
||
Recruiting |
NCT06173076 -
A Prospective Study to Evaluate Clinical Outcomes in Anti-LGI1 Encephalitis
|
||
Recruiting |
NCT03993262 -
Trial to Evaluate Efficacy and Safety of Bortezomib in Patients With Severe Autoimmune Encephalitis
|
Phase 2 | |
Recruiting |
NCT06033846 -
Efficacy and Safety of Adjunctive Minocycline in the Treatment of Autoimmune Encephalitis
|
Phase 2 | |
Recruiting |
NCT04372615 -
The ExTINGUISH Trial of Inebilizumab in NMDAR Encephalitis
|
Phase 2 | |
Recruiting |
NCT05177939 -
Phase III Clinical Study of NPB-01 in Patients With Autoimmune Encephalitis
|
Phase 3 | |
Active, not recruiting |
NCT06432803 -
Metabolic Imaging for Diagnosis and Prognostication of Autoimmune encephalitiS
|
||
Recruiting |
NCT06019975 -
FDG-PET in the Diagnosis of Autoimmune Encephalitis
|
||
Completed |
NCT05783947 -
Diagnostic Performance of a Commercial Assay for the Detection of Neuronal Antibodies
|
||
Not yet recruiting |
NCT06456736 -
Clinical Features and Prognostic Markers in Adult Patients With AE Requiring ICU Treatment
|
||
Completed |
NCT05825690 -
BRIEF TITLE * (in English and Sufficiently Descriptive) Role of MRI in Anti-LGI1 Encephalitis
|